Hemocompatibility modifiers for cross-linked polymeric material

1. A method of treating blood, blood product, plasma or physiologic fluid to provide increased shelf life of the blood, blood product or physiologic fluid; said method comprising contacting said blood, blood product or physiologic fluid with a sorbent, said sorbent comprising a plurality of solid forms and comprising a cross-linked polymeric material having a plurality of ligands attached to the surface of said cross-linked polymeric material comprising (i) zwitterionic moieties, (ii) oligo(ethylene glycol) moieties or (iii) mixtures thereof; said contacting comprising said sorbent sorbing inflammatory mediators and stimulators when said sorbent is (a) within a cartridge suitable for filtration of blood, blood product or physiologic fluid, (b) placed within a storage bag suitable for storing blood, blood product or physiologic fluid;

wherein said sorbent comprises particles having a diameter in the range for 0.1 micron meters to 2 centimeters,

wherein said particles are characterized as having a pore structure having a total volume of pore sizes in the range of from 10 Å to 10,000 Å that is between (a) greater than 0.5 cc/g dry polymer and (b) 3.0 cc/g dry polymer; wherein the ratio of pore volume between 10 Å to 3,000 Å in diameter to pore volume between 500 Å to 3,000 Å in diameter of the said cross-linked polymeric material is smaller than 7:1 and wherein the ratio of pore volume between 10 Å to 3,000 Å in diameter to pore volume between 10 Å to 6,000 Å in diameter of said cross-linked polymeric material is less than 2:1 and

wherein when said sorbent is contained within said cartridge or said storage bag, said sorbent being substantially free-flowing within said cartridge or said storage bag; and

wherein the inflammatory mediators and stimulators are selected from cytokines, thromboxanes, leukotrienes, platelet-activating factor, prostaglandins, glycoproteins, kinins, kininogens, complement factors, cell-adhesion molecules, superantigens, monokines, chemokines, interferons, free radicals, proteases, arachidonic acid metabolites, prostacyclins, beta endorphins, myocardial depressant factors, tetrahydrobiopterin, bradykinin, soluble CD40 ligand, hemoglobin, red cell particulates, membrane or cellular components, growth factors, prions, toxins, endotoxins, vasoactive substances, foreign antigens, microvesicles and antibodies;

wherein said sorbent comprises cross-linked polymeric material derived from the reaction of a cross-linker with one or more of the following polymerizable monomers: divinyl-benzene, styrene, ethylstyrene, acrylonitrile, butyl methacrylate, octyl methacrylate, butyl acrylate, octyl acrylate, cetyl methacrylate, cetyl acrylate, ethyl methacrylate, ethyl acrylate, vinyltoluene, vinylnaphthalene, vinylbenzyl alcohol, vinylformamide, methyl methacrylate, and methyl acrylate; and

wherein said zwitterionic moieties comprise one or more carboxybetaine and sulfobetaine zwitterionic moieties.

2. The method of claim 1 , wherein said zwitterionic moieties comprise at least one residue of carboxybetaine methacrylate.

3. The method of claim 1 , wherein said zwitterionic moieties comprise at least one group of the formula

4. The method of claim 1 , wherein the inflammatory mediators and stimulators are antibodies.

5. The method of claim 1 , wherein said zwitterionic moieties are covalently bonded to the surface of said cross-linked polymeric material.

6. The method of claim 1 , wherein said zwitterionic moieties are covalently bound to the surface of said cross-linked polymeric material by radical polymerization of ethylenically unsaturated zwitterionic monomers having a sulphobetaine group with an unsaturated group residing on the surface of said cross-linked polymeric material.

7. The method of claim 1 , wherein said sorbent is a biocompatible polymer.

8. The method of claim 1 , wherein said polymer is hemocompatible.

9. The method of claim 1 , wherein said particles comprise a carboxybetaine methacrylate coating.

10. The method of claim 1 , wherein the zwitterionic moieties are selected from:

11. The method of claim 1 , wherein the inflammatory mediators and stimulators comprise cytokines.

12. The method of claim 1 , wherein the oligo(ethylene glycol) moieties comprise at least one group of the formula:

where n is an integer from 3-8.